| Bel Air Care Center | |
| 2350 South Cherry Street, Alliance, Ohio 44601 | |
| (330) 821-3939 | |
| Name | Bel Air Care Center |
|---|---|
| Location | 2350 South Cherry Street, Alliance, Ohio |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 45 |
| Occupancy Rate | 83.56% |
| Medicare ID (CCN) | 366277 |
| Legal Business Name | David E Childs Jr. |
| Ownership Type | For Profit - Individual |
| NPI Number | 1528062171 |
| Organization Name | DAVID E CHILDS JR |
| Doing Business As | BEL AIR CARE CENTER |
| Address | 2350 Cherry Ave, Alliance, OH 44601 |
| Phone Number | 330-821-3939 |
News Archive
Foreign pharmaceutical companies on Wednesday accepted the decision of Ecuador's President Rafael Correa to enable the country "to bypass patents on 2,000 drugs in order to produce them locally or buy cheaper versions elsewhere," Agence France-Presse reports.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Stroke patients were almost twice as likely to be functionally independent-;mobile and able to perform daily tasks-;at 90 days post-stroke if they were treated by a specialized mobile stroke team that traveled to them to perform mechanical clot removal, compared to those who were transferred to a thrombectomy stroke center, according to research conducted within the Mount Sinai Health System and published today in Stroke, a journal of the American Stroke Association, a division of the American Heart Association.
Hospital for Special Surgery (HSS) plans to host a two-day international Osteoarthritis Summit in June 2011. The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together, for the first time, a truly comprehensive multidisciplinary group of world renowned scientists, thought-leaders and industry representatives from the United States, Canada, and Europe, to discuss all aspects of OA and develop a consensus document on future directions for OA research, prevention and treatment.
NanoInk, Inc.®, a global leader in nanotechnology, is pleased to announce the launch of its first completely configured protein array kit from its Nano BioDiscovery™ Division. Based on the patented Dip Pen Nanolithography® (DPN®) platform, NanoInk's fluorescent assays enable nanoscale detection of clinically relevant proteins.
› Verified 9 days ago
| NPI Number | 1619211646 |
| Address | 2350 Cherry Ave, Alliance, OH 44601 |
| Phone Number | 330-821-3939 |
News Archive
Foreign pharmaceutical companies on Wednesday accepted the decision of Ecuador's President Rafael Correa to enable the country "to bypass patents on 2,000 drugs in order to produce them locally or buy cheaper versions elsewhere," Agence France-Presse reports.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Stroke patients were almost twice as likely to be functionally independent-;mobile and able to perform daily tasks-;at 90 days post-stroke if they were treated by a specialized mobile stroke team that traveled to them to perform mechanical clot removal, compared to those who were transferred to a thrombectomy stroke center, according to research conducted within the Mount Sinai Health System and published today in Stroke, a journal of the American Stroke Association, a division of the American Heart Association.
Hospital for Special Surgery (HSS) plans to host a two-day international Osteoarthritis Summit in June 2011. The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together, for the first time, a truly comprehensive multidisciplinary group of world renowned scientists, thought-leaders and industry representatives from the United States, Canada, and Europe, to discuss all aspects of OA and develop a consensus document on future directions for OA research, prevention and treatment.
NanoInk, Inc.®, a global leader in nanotechnology, is pleased to announce the launch of its first completely configured protein array kit from its Nano BioDiscovery™ Division. Based on the patented Dip Pen Nanolithography® (DPN®) platform, NanoInk's fluorescent assays enable nanoscale detection of clinically relevant proteins.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Foreign pharmaceutical companies on Wednesday accepted the decision of Ecuador's President Rafael Correa to enable the country "to bypass patents on 2,000 drugs in order to produce them locally or buy cheaper versions elsewhere," Agence France-Presse reports.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Stroke patients were almost twice as likely to be functionally independent-;mobile and able to perform daily tasks-;at 90 days post-stroke if they were treated by a specialized mobile stroke team that traveled to them to perform mechanical clot removal, compared to those who were transferred to a thrombectomy stroke center, according to research conducted within the Mount Sinai Health System and published today in Stroke, a journal of the American Stroke Association, a division of the American Heart Association.
Hospital for Special Surgery (HSS) plans to host a two-day international Osteoarthritis Summit in June 2011. The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together, for the first time, a truly comprehensive multidisciplinary group of world renowned scientists, thought-leaders and industry representatives from the United States, Canada, and Europe, to discuss all aspects of OA and develop a consensus document on future directions for OA research, prevention and treatment.
NanoInk, Inc.®, a global leader in nanotechnology, is pleased to announce the launch of its first completely configured protein array kit from its Nano BioDiscovery™ Division. Based on the patented Dip Pen Nanolithography® (DPN®) platform, NanoInk's fluorescent assays enable nanoscale detection of clinically relevant proteins.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $7800 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 3.7 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.22 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 66.67 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.74 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 6.58 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 52 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0.65 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.74 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 98.39 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.33 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 23.19 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 29.71 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 0.72 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 56.31 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 99 | 82.93 |
News Archive
Foreign pharmaceutical companies on Wednesday accepted the decision of Ecuador's President Rafael Correa to enable the country "to bypass patents on 2,000 drugs in order to produce them locally or buy cheaper versions elsewhere," Agence France-Presse reports.
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved Tradjenta tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Stroke patients were almost twice as likely to be functionally independent-;mobile and able to perform daily tasks-;at 90 days post-stroke if they were treated by a specialized mobile stroke team that traveled to them to perform mechanical clot removal, compared to those who were transferred to a thrombectomy stroke center, according to research conducted within the Mount Sinai Health System and published today in Stroke, a journal of the American Stroke Association, a division of the American Heart Association.
Hospital for Special Surgery (HSS) plans to host a two-day international Osteoarthritis Summit in June 2011. The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together, for the first time, a truly comprehensive multidisciplinary group of world renowned scientists, thought-leaders and industry representatives from the United States, Canada, and Europe, to discuss all aspects of OA and develop a consensus document on future directions for OA research, prevention and treatment.
NanoInk, Inc.®, a global leader in nanotechnology, is pleased to announce the launch of its first completely configured protein array kit from its Nano BioDiscovery™ Division. Based on the patented Dip Pen Nanolithography® (DPN®) platform, NanoInk's fluorescent assays enable nanoscale detection of clinically relevant proteins.
› Verified 9 days ago
Altercare Of Alliance Ctr For Rehab & Nc Inc Location: 11750 Klinger Avenue Ne, Alliance, Ohio 44601 Phone: (330) 823-8263 | |
Mccrea Manor Nsng And Rehab Ctr Llc Location: 2040 Mccrea Street, Alliance, Ohio 44601 Phone: (330) 823-9005 | |
Canterbury Villa Of Alliance Location: 1785 Freshley Avenue, Alliance, Ohio 44601 Phone: (330) 821-4000 | |
Roselawn Gardens Nursing & Rehabilitation Location: 11999 Klinger Avenue Ne, Alliance, Ohio 44601 Phone: (330) 823-0618 | |